## **Aaron Ciechanover**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2004933/publications.pdf

Version: 2024-02-01

137 papers

30,713 citations

28274 55 h-index 125 g-index

147 all docs

147 docs citations

times ranked

147

30859 citing authors

#	Article	IF	CITATIONS
1	THE UBIQUITIN SYSTEM. Annual Review of Biochemistry, 1998, 67, 425-479.	11.1	7,702
2	Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death and Differentiation, 2018, 25, 486-541.	11.2	4,036
3	The Ubiquitin-Proteasome Proteolytic Pathway: Destruction for the Sake of Construction. Physiological Reviews, 2002, 82, 373-428.	28.8	3,696
4	The ubiquitin-proteasome proteolytic pathway. Cell, 1994, 79, 13-21.	28.9	1,751
5	Proteolysis: from the lysosome to ubiquitin and the proteasome. Nature Reviews Molecular Cell Biology, 2005, 6, 79-87.	37.0	919
6	The Ubiquitin Proteasome System in Neurodegenerative Diseases. Neuron, 2003, 40, 427-446.	8.1	909
7	Ubiquitin-mediated proteolysis: biological regulation via destruction. BioEssays, 2000, 22, 442-451.	2.5	764
8	Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies. Experimental and Molecular Medicine, 2015, 47, e147-e147.	7.7	650
9	The ubiquitin system. Nature Medicine, 2000, 6, 1073-1081.	30.7	625
10	Ubiquitin dependence of selective protein degradation demonstrated in the mammalian cell cycle mutant ts85. Cell, 1984, 37, 57-66.	28.9	530
11	Thermolability of ubiquitin-activating enzyme from the mammalian cell cycle mutant ts85. Cell, 1984, 37, 43-55.	28.9	530
12	The Ubiquitin Code in the Ubiquitin-Proteasome System and Autophagy. Trends in Biochemical Sciences, 2017, 42, 873-886.	<b>7.</b> 5	525
13	Mutation of the E6-AP Ubiquitin Ligase Reduces Nuclear Inclusion Frequency While Accelerating Polyglutamine-Induced Pathology in SCA1 Mice. Neuron, 1999, 24, 879-892.	8.1	482
14	THE UBIQUITIN-PROTEASOME PATHWAY AND PATHOGENESIS OF HUMAN DISEASES. Annual Review of Medicine, 1999, 50, 57-74.	12.2	426
15	N-terminal ubiquitination: more protein substrates join in. Trends in Cell Biology, 2004, 14, 103-106.	7.9	326
16	The life cycle of the 26S proteasome: from birth, through regulation and function, and onto its death. Cell Research, 2016, 26, 869-885.	12.0	266
17	Protein Quality Control by Molecular Chaperones in Neurodegeneration. Frontiers in Neuroscience, 2017, 11, 185.	2.8	245
18	Modes of regulation of ubiquitin-mediated protein degradation. Journal of Cellular Physiology, 2000, 182, 1-11.	4.1	242

#	Article	IF	CITATIONS
19	The ubiquitin-mediated proteolytic pathway: Mode of action and clinical implications. Journal of Cellular Biochemistry, 2000, 77, 40-51.	2.6	238
20	The unravelling of the ubiquitin system. Nature Reviews Molecular Cell Biology, 2015, 16, 322-324.	37.0	227
21	The Polycomb Protein Ring1B Generates Self Atypical Mixed Ubiquitin Chains Required for Its In Vitro Histone H2A Ligase Activity. Molecular Cell, 2006, 24, 701-711.	9.7	211
22	p62- and ubiquitin-dependent stress-induced autophagy of the mammalian 26S proteasome. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E7490-E7499.	7.1	205
23	The ubiquitinâ€mediated proteolytic pathway: mechanisms of recognition of the proteolytic substrate and involvement in the degradation of native cellular proteins. FASEB Journal, 1994, 8, 182-191.	0.5	198
24	Amino-terminal arginylation targets endoplasmic reticulum chaperone BiP for autophagy through p62Âbinding. Nature Cell Biology, 2015, 17, 917-929.	10.3	198
25	p62/SQSTM1/Sequestosome-1 is an N-recognin of the N-end rule pathway which modulates autophagosome biogenesis. Nature Communications, 2017, 8, 102.	12.8	178
26	Degradation of the E7 human papillomavirus oncoprotein by the ubiquitin-proteasome system: targeting via ubiquitination of the N-terminal residue. Oncogene, 2000, 19, 5944-5950.	5.9	165
27	The ubiquitin proteolytic system: From a vague idea, through basic mechanisms, and onto human diseases and drug targeting. Neurology, 2006, 66, S7-S19.	1.1	157
28	Role of arginine-tRNA in protein degradation by the ubiquitin pathway. Nature, 1987, 326, 808-811.	27.8	151
29	Degradation of the Epstein-Barr Virus Latent Membrane Protein 1 (LMP1) by the Ubiquitin-Proteasome Pathway. Journal of Biological Chemistry, 2000, 275, 23491-23499.	3.4	148
30	Intracellular Protein Degradation: From a Vague Idea, through the Lysosome and the Ubiquitin-Proteasome System, and onto Human Diseases and Drug Targeting (Nobel Lecture). Angewandte Chemie - International Edition, 2005, 44, 5944-5967.	13.8	146
31	The Size of the Proteasomal Substrate Determines Whether Its Degradation Will Be Mediated by Monoor Polyubiquitylation. Molecular Cell, 2012, 48, 87-97.	9.7	141
32	The ubiquitin-proteasome system and autophagy: Coordinated and independent activities. International Journal of Biochemistry and Cell Biology, 2016, 79, 403-418.	2.8	135
33	The ubiquitin system: pathogenesis of human diseases and drug targeting. Biochimica Et Biophysica Acta - Molecular Cell Research, 2004, 1695, 3-17.	4.1	131
34	Synthetic polyubiquitinated $\hat{l}_{\pm}$ -Synuclein reveals important insights into the roles of the ubiquitin chain in regulating its pathophysiology. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 17726-17731.	7.1	130
35	The complexity of recognition of ubiquitinated substrates by the 26S proteasome. Biochimica Et Biophysica Acta - Molecular Cell Research, 2014, 1843, 86-96.	4.1	130
36	Numerous proteins with unique characteristics are degraded by the 26S proteasome following monoubiquitination. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E4639-47.	7.1	127

3

#	Article	IF	CITATIONS
37	Structural Motifs Involved in Ubiquitin-Mediated Processing of the NF- $\hat{l}^{\circ}$ B Precursor p105: Roles of the Glycine-Rich Region and a Downstream Ubiquitination Domain. Molecular and Cellular Biology, 1999, 19, 3664-3673.	2.3	112
38	Intracellular protein degradation: From a vague idea thru the lysosome and the ubiquitin–proteasome system and onto human diseases and drug targeting. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2012, 1824, 3-13.	2.3	102
39	Intracellular protein degradation: From a vague idea through the lysosome and the ubiquitin–proteasome system and onto human diseases and drug targeting. Bioorganic and Medicinal Chemistry, 2013, 21, 3400-3410.	3.0	101
40	The Ubiquitin System: From Basic Mechanisms to the Patient Bed. IUBMB Life, 2004, 56, 193-201.	3.4	97
41	The N-Degron Pathway Mediates ER-phagy. Molecular Cell, 2019, 75, 1058-1072.e9.	9.7	96
42	Degradation of ornithine decarboxylase in mammalian cells is ATP dependent but ubiquitin independent. FEBS Journal, 1989, 185, 469-474.	0.2	89
43	KPC1-Mediated Ubiquitination and Proteasomal Processing of NF- $\hat{l}^{\Omega}$ B1 p105 to p50 Restricts Tumor Growth. Cell, 2015, 161, 333-347.	28.9	89
44	Modification by Single Ubiquitin Moieties Rather Than Polyubiquitination Is Sufficient for Proteasomal Processing of the p105 NF-ÎB Precursor. Molecular Cell, 2009, 33, 496-504.	9.7	88
45	Nonenzymatic Polyubiquitination of Expressed Proteins. Journal of the American Chemical Society, 2014, 136, 2665-2673.	13.7	88
46	Regulation of the polycomb protein Ring1B by self-ubiquitination or by E6-AP may have implications to the pathogenesis of Angelman syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 6788-6793.	7.1	85
47	On the involvement of calpains in the degradation of the tumor suppressor protein p53. FEBS Letters, 1997, 406, 17-22.	2.8	82
48	Ubiquitin degradation with its substrate, or as a monomer in a ubiquitination-independent mode, provides clues to proteasome regulation. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 11907-11912.	7.1	67
49	Degradation of the Id2 developmental regulator: targeting via N-terminal ubiquitination. Biochemical and Biophysical Research Communications, 2004, 314, 505-512.	2.1	65
50	Intracellular protein degradation: From a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Best Practice and Research in Clinical Haematology, 2017, 30, 341-355.	1.7	64
51	De novo macrocyclic peptides that specifically modulate Lys48-linked ubiquitin chains. Nature Chemistry, 2019, 11, 644-652.	13.6	63
52	Differential interaction of plakoglobin and $\hat{l}^2$ -catenin with the ubiquitin-proteasome system. Oncogene, 2000, 19, 1992-2001.	5.9	61
53	Ubiquitin-mediated degradation of cellular proteins in health and disease. Hepatology, 2002, 35, 3-6.	7.3	61
54	Dual Effects of lκB Kinase β-Mediated Phosphorylation on p105 Fate: SCF β-TrCP -Dependent Degradation and SCF β-TrCP -Independent Processing. Molecular and Cellular Biology, 2004, 24, 475-486.	2.3	57

#	Article	IF	CITATIONS
55	Intracellular Protein Degradation: From a Vague Idea Thru the Lysosome and the Ubiquitin-Proteasome System and onto Human Diseases and Drug Targeting <sup>*</sup> . Experimental Biology and Medicine, 2006, 231, 1197-1211.	2.4	56
56	N-terminal arginylation generates a bimodal degron that modulates autophagic proteolysis. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E2716-E2724.	7.1	56
57	The Lysine48â€Based Polyubiquitin Chain Proteasomal Signal: Not a Single Child Anymore. Angewandte Chemie - International Edition, 2013, 52, 192-198.	13.8	54
58	Ubiquitin Binding by a CUE Domain Regulates Ubiquitin Chain Formation by ERAD E3 Ligases. Molecular Cell, 2013, 50, 528-539.	9.7	54
59	Ubiquitin-Proteasome-mediated Degradation of Keratin Intermediate Filaments in Mechanically Stimulated A549 Cells. Journal of Biological Chemistry, 2008, 283, 25348-25355.	3.4	50
60	Intracellular Protein Degradation From a Vague Idea through the Lysosome and the Ubiquitinâ€Proteasome System and on to Human Diseases and Drug Targeting. Annals of the New York Academy of Sciences, 2007, 1116, 1-28.	3.8	49
61	Diverse fate of ubiquitin chain moieties: The proximal is degraded with the target, and the distal protects the proximal from removal and recycles. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 7805-7812.	7.1	48
62	Intracellular Protein Degradation: From a Vague Idea through the Lysosome and the Ubiquitin-Proteasome System and onto Human Diseases and Drug Targeting. Neurodegenerative Diseases, 2012, 10, 7-22.	1.4	42
63	p62-containing, proteolytically active nuclear condensates, increase the efficiency of the ubiquitin–proteasome system. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	40
64	On the linkage between the ubiquitin-proteasome system and the mitochondria. Biochemical and Biophysical Research Communications, 2016, 473, 80-86.	2.1	39
65	Complete reconstitution of conjugation and subsequent degradation of the tumor suppressor protein p53 by purified components of the ubiquitin proteolytic system. FEBS Letters, 1994, 348, 126-130.	2.8	38
66	The 26S proteasome of the yeastSaccharomyces cerevisiae. FEBS Letters, 1994, 355, 69-75.	2.8	38
67	Degradation of Ornithine Decarboxylase by the Mammalian and Yeast 26S Proteasome Complexes Requires all the Components of the Protease. FEBS Journal, 1995, 229, 276-283.	0.2	38
68	The endoplasmic reticulum–residing chaperone BiP is short-lived and metabolized through N-terminal arginylation. Science Signaling, 2018, 11, .	3.6	38
69	p62 at the crossroad of the ubiquitin-proteasome system and autophagy. Oncotarget, 2016, 7, 83833-83834.	1.8	38
70	The Ubiquitin-Mediated Proteolytic Pathway. Brain Pathology, 1993, 3, 67-75.	4.1	37
71	Regulation of autophagic proteolysis by the N-recognin SQSTM1/p62 of the N-end rule pathway. Autophagy, 2018, 14, 359-361.	9.1	36
72	The ubiquitin-proteasome system: A potential therapeutic target for heart failure. Journal of Heart and Lung Transplantation, 2017, 36, 708-714.	0.6	34

#	Article	IF	CITATIONS
73	Monoubiquitination joins polyubiquitination as an esteemed proteasomal targeting signal. BioEssays, 2017, 39, 1700027.	2.5	34
74	Epigenetic Regulation of KPC1 Ubiquitin Ligase Affects the NF-κB Pathway in Melanoma. Clinical Cancer Research, 2017, 23, 4831-4842.	7.0	33
75	Multiple Sclerosis Autoantigen Myelin Basic Protein Escapes Control by Ubiquitination during Proteasomal Degradation. Journal of Biological Chemistry, 2014, 289, 17758-17766.	3.4	31
76	Tracing the history of the ubiquitin proteolytic system: The pioneering article. Biochemical and Biophysical Research Communications, 2009, 387, 1-10.	2.1	29
77	Ubiquitination of specific mitochondrial matrix proteins. Biochemical and Biophysical Research Communications, 2016, 475, 13-18.	2.1	29
78	Gliomaâ€derived cancer stem cells are hypersensitive to proteasomal inhibition. EMBO Reports, 2017, 18, 150-168.	4.5	29
79	The Ubiquitin Proteolytic System: From an Idea to the Patient Bed. Proceedings of the American Thoracic Society, 2006, 3, 21-31.	3.5	28
80	Linking ubiquitin, parkin and synphilin-1. Nature Medicine, 2001, 7, 1108-1109.	30.7	27
81	Two distinct ubiquitin-dependent mechanisms are involved in NF-κB p105 proteolysis. Biochemical and Biophysical Research Communications, 2006, 345, 7-13.	2.1	26
82	N-Terminal Ubiquitination., 2005, 301, 255-270.		25
83	Intracellular Protein Degradation: From a Vague Idea thru the Lysosome and the Ubiquitin-Proteasome System and onto Human Diseases and Drug Targeting. Hematology American Society of Hematology Education Program, 2006, 2006, 1-12.	2.5	25
84	The N-terminal cysteine is a dual sensor of oxygen and oxidative stress. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	24
85	Degradation of tyrosine aminotransferase (TAT) via the ubiquitin-proteasome pathway. FEBS Letters, 1997, 405, 175-180.	2.8	23
86	Modulation of SQSTM1/p62 activity by N-terminal arginylation of the endoplasmic reticulum chaperone HSPA5/GRP78/BiP. Autophagy, 2016, 12, 426-428.	9.1	23
87	Stress-induced polyubiquitination of proteasomal ubiquitin receptors targets the proteolytic complex for autophagic degradation. Autophagy, 2017, 13, 759-760.	9.1	23
88	The ubiquitin-proteasome system and activation of NF-κB: involvement of the ubiquitin ligase KPC1 in p105 processing and tumor suppression. Molecular and Cellular Oncology, 2015, 2, e1054552.	0.7	22
89	Downregulation of the Ubiquitin-E3 Ligase RNF123 Promotes Upregulation of the NF-κB1 Target SerpinE1 in Aggressive Glioblastoma Tumors. Cancers, 2020, 12, 1081.	3.7	22
90	Generation of free ubiquitin chains is up-regulated in stress and facilitated by the HECT domain ubiquitin ligases UFD4 and HUL5. Biochemical Journal, 2012, 444, 611-617.	3.7	21

#	Article	IF	CITATIONS
91	Post-translational modification profiling $\hat{a}\in$ A novel tool for mapping the protein modification landscape in cancer. Experimental Biology and Medicine, 2016, 241, 1475-1482.	2.4	21
92	Degradation of MyoD by the ubiquitin pathway: regulation by specific DNA-binding and identification of a novel site for ubiquitination. Molecular Biology Reports, 1999, 26, 59-64.	2.3	20
93	Regulation of the ubiquitin-mediated proteolytic pathway: Role of the substrate ?-NH2 group and of transfer RNA. Journal of Cellular Biochemistry, 1987, 34, 81-100.	2.6	18
94	The testis-specific USP26 is a deubiquitinating enzyme of the ubiquitin ligase Mdm2. Biochemical and Biophysical Research Communications, 2017, 482, 106-111.	2.1	18
95	Site-specific ubiquitination of pathogenic huntingtin attenuates its deleterious effects. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 18661-18669.	7.1	18
96	Excess of the NF-Ä,B p50 subunit generated by the ubiquitin ligase KPC1 suppresses tumors via PD-L1– and chemokines-mediated mechanisms. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 29823-29831.	7.1	18
97	<i>In vivo</i> modulation of ubiquitin chains by <i>N</i> -methylated non-proteinogenic cyclic peptides. RSC Chemical Biology, 2021, 2, 513-522.	4.1	16
98	KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple Myeloma. Frontiers in Oncology, 2019, 9, 1137.	2.8	15
99	Affinity Maturation of Macrocyclic Peptide Modulators of Lys48â€Linked Diubiquitin by a Twofold Strategy. Chemistry - A European Journal, 2020, 26, 8022-8027.	3.3	15
100	Ubiquitin–mediated proteolysis and male sterility. Nature Medicine, 1996, 2, 1188-1190.	30.7	14
101	Identification of UBact, a ubiquitin-like protein, along with other homologous components of a conjugation system and the proteasome in different gram-negative bacteria. Biochemical and Biophysical Research Communications, 2017, 483, 946-950.	2.1	12
102	Immune defects caused by mutations in the ubiquitin system. Journal of Allergy and Clinical Immunology, 2017, 139, 743-753.	2.9	12
103	Nucleoporin-93 reveals a common feature of aggressive breast cancers: robust nucleocytoplasmic transport of transcription factors. Cell Reports, 2022, 38, 110418.	6.4	12
104	Identification of proteins regulated by the proteasome following induction of endoplasmic reticulum stress. Biochemical and Biophysical Research Communications, 2019, 517, 188-192.	2.1	11
105	Evolutionary Origin of the Activation Step During Ubiquitin-dependent Protein Degradation. , 2005, , 21-43.		9
106	The p105 NF-Ä,B precursor is a pseudo substrate of the ubiquitin ligase FBXO7, and its binding to the ligase stabilizes it and results in stimulated cell proliferation. Biochemical and Biophysical Research Communications, 2021, 558, 224-230.	2.1	8
107	Intracellular Protein Degradation: From a Vague Idea through the Lysosome and the Ubiquitin-Proteasome System and onto Human Diseases and Drug Targeting. Rambam Maimonides Medical Journal, 2012, 3, e0001.	1.0	7
108	Israel–Gaza conflict. Lancet, The, 2014, 384, e34-e37.	13.7	6

#	Article	IF	Citations
109	Ubiquitin-mediated degradation of tyrosine aminotransferase (TAT) in vitro and in vivo. Molecular Biology Reports, 1997, 24, 27-33.	2.3	5
110	A short binding site in the KPC1 ubiquitin ligase mediates processing of NF- $\hat{\mathbb{P}}$ B1 p105 to p50: A potential for a tumor-suppressive PROTAC. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	5
111	Exploiting the ubiquitin system in myeloid malignancies. From basic research to drug discovery in MDS and AML. Blood Reviews, 2022, , 100971.	5.7	5
112	The Ubiquitin System: Historical Perspective. Proceedings of the American Thoracic Society, 2010, 7, 11-12.	3.5	4
113	Role of the ubiquitin ligase KPC1 in NF-κB activation and tumor suppression. Journal of Analytical Science and Technology, 2016, 7, .	2.1	4
114	Modulation of the cell cycle regulating transcription factor E2F1 pathway by the proteasome following amino acid starvation. Biochemical and Biophysical Research Communications, 2019, 513, 721-725.	2.1	4
115	A possible non-proteolytic role of ubiquitin conjugation in alleviating the pathology of Huntingtin's aggregation. Cell Death and Differentiation, 2021, 28, 814-817.	11.2	4
116	In-depth characterization of ubiquitin turnover in mammalian cells by fluorescence tracking. Cell Chemical Biology, 2021, 28, 1192-1205.e9.	5.2	4
117	A novel small molecule CXCR4 antagonist potently mobilizes hematopoietic stem cells in mice and monkeys. Stem Cell Research and Therapy, 2021, 12, 17.	5.5	4
118	RING Fingers and Relatives: Determinators of Protein Fate. , 2005, , 44-101.		3
119	The COP9 Signalosome: Its Possible Role in the Ubiquitin System. , 2005, , 348-369.		3
120	Monitoring stress-induced autophagic engulfment and degradation of the 26S proteasome in mammalian cells. Methods in Enzymology, 2019, 619, 337-366.	1.0	3
121	A fragment integrational approach to GPCR inhibition: Identification of a high affinity small molecule CXCR4 antagonist. European Journal of Medicinal Chemistry, 2022, 231, 114150.	5.5	3
122	The 26S Proteasome. , 2005, , 220-247.		2
123	The Structural Biology of Ubiquitin-Protein Ligases. , 2005, , 156-189.		2
124	Proteasome phase separation: a novel layer of quality control. Cell Research, 2020, 30, 374-375.	12.0	2
125	Intracellular protein degradation: from a vague idea through the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Medicina, 2010, 70, 105-19.	0.6	2
126	Brief History of Protein Degradation and the Ubiquitin System., 2005, , 1-9.		1

#	Article	IF	CITATIONS
127	Ubiquitin-conjugating Enzymes. , 2005, , 102-134.		1
128	Intracellular Protein Degradation: From a Vague Idea, through the Lysosome and the Ubiquitin-Proteasome System, and onto Human Diseases and Drug Targeting Nobel Lecture. Israel Journal of Chemistry, 2006, 46, 121-136.	2.3	1
129	Molecular Machines for Protein Degradation. , 2005, , 248-287.		0
130	N-terminal Ubiquitination: No Longer Such a Rare Modification. , 2005, , 10-20.		0
131	The SCF Ubiquitin E3 Ligase. , 2005, , 135-155.		O
132	Proteasome Regulator, PA700 (19S Regulatory Particle)., 2005,, 288-316.		0
133	Bioinformatics of Ubiquitin Domains and Their Binding Partners. , 2005, , 318-347.		O
134	The Deubiquitinating Enzymes., 2005,, 190-219.		0
135	The bedside-bench-bedside cycle: Robert Lefkowitz and GPCRs. Science Signaling, 2021, 14, .	3.6	O
136	How multi-component cascades operate in cells: lessons from the ubiquitin system-containing liquid-separated condensates. Molecular and Cellular Oncology, 2021, 8, 1989939.	0.7	0
137	N-terminal Ubiquitination: No Longer Such a Rare Modification. , 0, , 10-20.		O